The LRRK2 G2019S transgenic mouse model expresses the most common pathogenic mutation in LRRK2 (leucine-rich repeat kinase 2), which causes autosomal dominant Parkinson's disease. This model enables study of kinase hyperactivation and testing of LRRK2-targeted therapeutics.
| Component |
Details |
| Promoter |
TetO (tetrahydropyridine-responsive) or ROSA26 |
| Gene |
Human LRRK2 with G2019S mutation |
| Expression |
Conditional (tetracycline-controlled) or constitutive |
| Background |
C57BL/6J |
The G2019S mutation is the most common pathogenic LRRK2 variant:
- Location: Kinase domain, activation loop
- Effect: Increases kinase activity 2-3 fold
- Prevalence: ~5% familial PD, ~1% idiopathic PD
- Penetrance: ~70% by age 80
The G2019S mutation causes constitutive kinase activation:
- Rab phosphorylation: Enhanced phosphorylation of Rab substrates (Rab8A, Rab10, Rab12)
- Lysosomal dysfunction: Altered lysosomal trafficking and cathepsin activity
- Autophagy impairment: Dysregulated autophagic flux
- Cytoskeletal disruption: Altered microtubule dynamics
- Mitochondrial dysfunction: Reduced complex I activity, increased ROS
- Synaptic dysfunction: Altered dopamine release
- Neuroinflammation: Microglial activation
| Marker |
Change |
Timepoint |
| pRab10 |
Increased |
2-3 months |
| pSer129 α-syn |
Increased |
6-12 months |
| Lamp2 |
Altered |
6 months |
| Cathepsin D |
Reduced |
12 months |
- Early (3-6 months): Minimal motor deficits
- Mid (6-12 months): Mild gait and coordination changes
- Late (12+ months): Moderate rotarod deficits, reduced spontaneous movement
- Subtle dopaminergic changes: Normal neuron counts but altered function
- α-Synuclein pathology: Phosphorylation and aggregation in some models
- Glial activation: Age-dependent microgliosis
- LRRK2 kinase inhibitors: DNL151 (DNL151), ABBV-487, others
- Antisense oligonucleotides: BIIB100
- Autophagy modulators: Trehalose
- Neuroprotective agents: Mitochondrial protectants
- pRab10 in CSF: Pharmacodynamic marker for kinase inhibition
- Neurofilament light chain: Neurodegeneration marker
- PET imaging: LRRK2 expression imaging (in development)
¶ Advantages and Limitations
- Genetic relevance: Expresses common familial PD mutation
- Kinase hyperactivity model: Enables kinase inhibitor testing
- Conditional expression: Temporal control with Tet systems
- Progressive phenotype: Age-dependent changes
- Variable phenotype: Less robust than toxin or α-syn models
- Late onset: Mild phenotype requires aged animals
- Incomplete penetrance: Not all transgenic lines show pathology
- Species differences: Mouse LRRK2 differs from human in some aspects
| Model |
Type |
Expression |
Phenotype Strength |
| BAC LRRK2 G2019S |
Transgenic |
Endogenous-like |
Moderate |
| AAV-LRRK2 G2019S |
Viral |
High, regional |
Moderate |
| Knockin G2019S |
Gene-edited |
Endogenous |
Mild to moderate |
| iPSC neurons |
Cellular |
Patient-derived |
Variable |
- Gong et al., 2021 - LRRK2 knockin mice
- Steger et al., 2016 - LRRK2 kinase activity in vivo
- Daher et al., 2015 - AAV-LRRK2 G2019S model
- Cookson, 2010 - LRRK2 function and dysfunction
- Javed et al., 2019 - LRRK2 in Parkinson's disease